Valeo Financial Statements From 2010 to 2024
| VPHIF Stock | USD 0.05 0.00 0.00% |
Check Valeo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Valeo Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Valeo financial statements analysis is a perfect complement when working with Valeo Pharma Valuation or Volatility modules.
Valeo |
Valeo Pharma Company Return On Equity Analysis
Valeo Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Valeo Pharma Return On Equity | -16.0 |
Most of Valeo Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Valeo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Valeo Pharma has a Return On Equity of -16.0041. This is 33.23% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is notably higher than that of the company.
Valeo Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Valeo Pharma's current stock value. Our valuation model uses many indicators to compare Valeo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Valeo Pharma competition to find correlations between indicators driving Valeo Pharma's intrinsic value. More Info.Valeo Pharma is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Valeo Pharma's earnings, one of the primary drivers of an investment's value.About Valeo Pharma Financial Statements
Valeo Pharma stakeholders use historical fundamental indicators, such as Valeo Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Valeo Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Valeo Pharma's assets and liabilities are reflected in the revenues and expenses on Valeo Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Valeo Pharma. Please read more on our technical analysis and fundamental analysis pages.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. The company was incorporated in 2003 and is headquartered in Kirkland, Canada. Valeo Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 100 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Valeo Pink Sheet
Valeo Pharma financial ratios help investors to determine whether Valeo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valeo with respect to the benefits of owning Valeo Pharma security.